PriceTargets.com logo

BeOne Medicines - ONC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $389.18
  • Forecasted Upside: 37.87%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$282.29 As of 03/18/2026 05:00 PM ET
▼ -5.04 (-1.75%)

This chart shows the closing price for ONC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New BeOne Medicines Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONC

Analyst Price Target is $389.18
▲ +37.87% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for BeOne Medicines in the last 3 months. The average price target is $389.18, with a high forecast of $425.00 and a low forecast of $290.00. The average price target represents a 37.87% upside from the last price of $282.29.

This chart shows the closing price for ONC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in BeOne Medicines. This rating has held steady since September 2025, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/23/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2025
  • 1 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2025
  • 0 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
12/18/2025
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
2/16/2026
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
3/18/2026

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/16/2026Jefferies Financial GroupDowngradeBuy ➝ Hold$420.00 ➝ $290.00
2/27/2026Truist FinancialBoost TargetBuy ➝ Buy$400.00 ➝ $412.00
2/27/2026GuggenheimBoost TargetBuy ➝ Buy$400.00 ➝ $410.00
2/27/2026BarclaysBoost TargetOverweight ➝ Overweight$394.00 ➝ $405.00
2/26/2026Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$417.00 ➝ $425.00
2/4/2026BarclaysBoost TargetOverweight ➝ Overweight$385.00 ➝ $394.00
1/21/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
1/12/2026Sanford C. BernsteinUpgradeHold ➝ Outperform$414.00
1/8/2026Morgan StanleyReiterated RatingOverweight ➝ Overweight$405.00
12/17/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform
11/24/2025Truist FinancialSet Target$400.00
11/24/2025Truist FinancialInitiated CoverageBuy$400.00
11/18/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$395.00 ➝ $408.00
11/17/2025Jefferies Financial GroupReiterated RatingBuy ➝ Buy$420.00
11/10/2025CitigroupBoost TargetBuy ➝ Buy$399.00 ➝ $405.00
11/7/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$374.00 ➝ $395.00
11/7/2025Citizens JmpBoost TargetMarket Outperform ➝ Market Outperform$348.00 ➝ $396.00
10/28/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
10/20/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$350.00 ➝ $383.00
10/8/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$345.00 ➝ $385.00
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
9/18/2025Zacks ResearchUpgradeHold ➝ Strong-Buy
9/18/2025BarclaysInitiated CoverageOverweight$385.00
8/7/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$349.00 ➝ $364.00
8/7/2025GuggenheimBoost TargetBuy ➝ Buy$350.00 ➝ $365.00
7/17/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$321.00 ➝ $345.00
7/16/2025Royal Bank Of CanadaBoost TargetOutperform ➝ Outperform$311.00 ➝ $349.00
6/27/2025Morgan StanleyBoost TargetOverweight ➝ Overweight$313.00 ➝ $330.00
6/27/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$317.00 ➝ $321.00
6/27/2025Royal Bank Of CanadaUpgradeOutperform ➝ Moderate Buy$311.00
5/8/2025Royal Bank Of CanadaLower TargetOutperform ➝ Outperform$312.00 ➝ $311.00
5/8/2025GuggenheimBoost TargetBuy ➝ Buy$348.00 ➝ $350.00
4/28/2025Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$312.00 ➝ $312.00
4/24/2025TD SecuritiesReiterated RatingBuy ➝ Buy$334.00 ➝ $334.00
4/21/2025JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$311.00 ➝ $317.00
4/16/2025GuggenheimReiterated RatingBuy ➝ Buy
4/10/2025GuggenheimReiterated RatingBuy ➝ Buy$348.00 ➝ $348.00
4/7/2025Royal Bank Of CanadaInitiated CoverageOutperform$312.00
4/7/2025Royal Bank Of CanadaUpgradeModerate Buy$312.00
3/13/2025Sanford C. BernsteinSet Target$259.00
3/3/2025Bank of AmericaUpgradeNeutral ➝ Buy$207.00 ➝ $320.00
2/28/2025GuggenheimReiterated RatingBuy ➝ Buy
2/28/2025Citizens JmpSet Target$348.00
2/28/2025Macquarie InfrastructureBoost TargetOutperform ➝ Outperform$259.00 ➝ $313.00
(Data available from 3/19/2021 forward)

News Sentiment Rating

0.94 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/21/2025
  • 8 very positive mentions
  • 15 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
9/20/2025
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/20/2025
  • 9 very positive mentions
  • 20 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
11/19/2025
  • 6 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/19/2025
  • 2 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/18/2026
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/17/2026
  • 20 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2026

Current Sentiment

  • 20 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

BeOne Medicines logo
BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.
Read More

Today's Range

Now: $282.29
Low: $281.04
High: $286.87

50 Day Range

MA: $332.21
Low: $282.29
High: $370.64

52 Week Range

Now: $282.29
Low: $196.45
High: $385.22

Volume

407,099 shs

Average Volume

287,479 shs

Market Capitalization

$30.96 billion

P/E Ratio

112.02

Dividend Yield

N/A

Beta

0.53

Frequently Asked Questions

What sell-side analysts currently cover shares of BeOne Medicines?

The following Wall Street sell-side analysts have issued stock ratings on BeOne Medicines in the last twelve months: Barclays PLC, Citigroup Inc., Citizens Jmp, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Royal Bank Of Canada, Sanford C. Bernstein, TD Securities, Truist Financial Corporation, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for ONC.

What is the current price target for BeOne Medicines?

0 Wall Street analysts have set twelve-month price targets for BeOne Medicines in the last year. Their average twelve-month price target is $389.18, suggesting a possible upside of 37.9%. Royal Bank Of Canada has the highest price target set, predicting ONC will reach $425.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $290.00 for BeOne Medicines in the next year.
View the latest price targets for ONC.

What is the current consensus analyst rating for BeOne Medicines?

BeOne Medicines currently has 1 sell rating, 2 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ONC.

What other companies compete with BeOne Medicines?

Other companies that are similar to BeOne Medicines include GSK, Sanofi, Takeda Pharmaceutical, argenex and Teva Pharmaceutical Industries. Learn More about companies similar to BeOne Medicines.

How do I contact BeOne Medicines' investor relations team?

BeOne Medicines' physical mailing address is C/O MOURANT GOVERNANCE SERVICES (CAYMAN), 94 SOLARIS AVENUE, CAMANA BAY, GRAND CAYMAN, E9, KY1-1108. The company's listed phone number is 13459494123 and its investor relations email address is [email protected]. The official website for BeOne Medicines is beigene.com. Learn More about contacing BeOne Medicines investor relations.